Brought to you by 
Jounce gets $261mm up front in major Celgene immuno-oncology deal; deal ends
15 Oct 2021
Executive Summary
Jounce Therapeutics Inc. and Celgene Corp. teamed up to co-develop and sell Jounce's lead immuno-oncology candidate JTX2011 and up to five additional early-stage immunotherapies.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Jounce gets $261mm up front in major Celgene immuno-oncology deal; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice